Home> Products> Inhibitors> BMS-833923-CAS 1059734-66-5
price inquiry for CAS:1059734-66-5, Product:BMS-833923
For research use only. We do not sell to patients.

BMS-833923 CAS: 1059734-66-5

Category: Inhibitors
Product Name: BMS-833923
Cat No: I000303
CAS No: 1059734-66-5
Synonyms: N-[2-methyl-5-(methylaminomethyl)phenyl]-4-[(4-phenylquinazolin-2-yl)amino]benzamide
Molecular Formula: C30H27N5O
Molecular Weight: 473.6
InChI: InChI=1S/C30H27N5O/c1-20-12-13-21(19-31-2)18-27(20)33-29(36)23-14-16-24(17-15-23)32-30-34-26-11-7-6-10-25(26)28(35-30)22-8-4-3-5-9-22/h3-18,31H,19H2,1-2H3,(H,33,36)(H,32,34,35)
Solubility: in DMSO > 10 mM
Target: Smoothened
IC50: 6-35 nM [1]
Storage: Store at -20°C
CAS 1059734-66-5,BMS-833923
  • Description

BMS-833923 (XL-139) is an orally bioavailable small-molecule inhibitor of Smoothened with potential antineoplastic activity; inhibits BODIPY cyclopamine binding to SMO in a dose-dependent manner with an IC50 of 21 nM.
IC50 Value: 6-35 nM [1]
Target: Smoothened
SMO antagonist BMS-833923 inhibits the sonic hedgehog (SHH) pathway protein SMO, which may result in a suppression of the SHH signaling pathway.
in vitro: In vitro, BMS-833923 inhibits the expression of downstream effectors in the HH pathway (GLI1 and PTCH1) in cell lines that express wild-type SMO and those which express activated mutant forms of SMO (IC50values of 6-35 nM). In FACS-based binding assays, BMS-833923 inhibits BODIPY cyclopamine binding to SMO in a dose-dependent manner with an IC50 of 21 nM [1].
in vivo: Pharmacodynamic studies show that BMS-833923 robustly inhibits HH pathway activity with along duration of action after a single oral dose in medulloblastoma and pancreatic carcinoma xenograft models. The pharmacodynamic effects of BMS-833923 observed in these models translate into tumor growth inhibition at well-tolerated doses [1].
Clinical trial: Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923). Phase 2

  • Spec

Appearance:white solid powder
Purity: > 98%

  • References

[1]. Steven B, et al. Abstract B192: Preclinical characterization of BMS-833923 (XL139), a hedgehog (HH) pathway inhibitor in early clinical development. Molecular Cancer Therapeutics: December 2009; Volume 8, Issue 12, Supplement 1.

price inquiry for CAS:1059734-66-5, Product:BMS-833923